Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Why BlueScope, Firefinch, Monash IVF, and South32 shares are pushing higher
Why Imugene, Integrated Research, Monash IVF, and Step One shares are sinking
Why A2 Milk, Gold Road, GrainCorp, and Monash IVF shares are dropping
Why Block, IDP Education, Monash IVF, and Xero shares are dropping
2 ASX small-cap shares breaking multi-year highs today
The Monash IVF (ASX:MVF) share price is gaining 6% today. Here’s why
4 ASX shares tipped for buybacks in 2022: expert
Post-COVID baby boom? That could supercharge this ASX share
|07 Mar 2022||$0.0220||100.00%||Interim||04 Apr 2022|
|09 Sep 2021||$0.0210||100.00%||Final||08 Oct 2021|
|09 Mar 2021||$0.0210||100.00%||Interim||07 Apr 2021|
|05 Mar 2020||$0.0210||100.00%||Interim||02 Oct 2020|
|05 Sep 2019||$0.0300||100.00%||Final||11 Oct 2019|
|06 Sep 2018||$0.0260||100.00%||Final||12 Oct 2018|
|08 Mar 2018||$0.0340||100.00%||Interim||06 Apr 2018|
|06 Sep 2017||$0.0450||100.00%||Final||13 Oct 2017|
|02 Mar 2017||$0.0430||100.00%||Interim||07 Apr 2017|
|06 Sep 2016||$0.0450||100.00%||Final||14 Oct 2016|
|08 Mar 2016||$0.0400||100.00%||Interim||08 Apr 2016|
|09 Sep 2015||$0.0370||100.00%||15 Oct 2015|
|12 Mar 2015||$0.0325||100.00%||08 Apr 2015|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Monash IVF Group Ltd is a specialist assisted reproductive services provider. The company offers specialist diagnostic obstetric and gynaecological ultrasound and fertility treatments. The company's operating segment includes Australia andInternational. It generates maximum revenue from the Australian segment. Australian segment is a provider of Assisted Reproductive Services, Ultrasound, and other related services. The International segment is a provider of Assisted Reproductive Services in Malaysia.
|20 May 2022||$1.10||$0.00||0.00%||947,063||$1.06||$1.12||$1.06|
|19 May 2022||$1.09||$-0.02||-1.79%||452,012||$1.09||$1.11||$1.08|
|18 May 2022||$1.12||$0.06||5.69%||1,331,421||$1.12||$1.12||$1.06|
|17 May 2022||$1.06||$0.02||1.94%||752,703||$1.02||$1.07||$1.02|
|16 May 2022||$1.03||$-0.03||-2.83%||12,248,512||$1.05||$1.09||$1.01|
|13 May 2022||$1.06||$-0.04||-3.64%||2,047,163||$1.06||$1.08||$1.00|
|12 May 2022||$1.10||$-0.07||-5.98%||2,126,128||$1.17||$1.18||$1.09|
|11 May 2022||$1.17||$-0.01||-0.85%||232,016||$1.18||$1.18||$1.17|
|10 May 2022||$1.18||$-0.03||-2.48%||485,303||$1.19||$1.20||$1.16|
|09 May 2022||$1.21||$-0.01||-0.82%||1,036,326||$1.22||$1.22||$1.19|
|06 May 2022||$1.22||$-0.02||-1.61%||976,590||$1.24||$1.24||$1.21|
|05 May 2022||$1.24||$0.01||0.82%||1,466,618||$1.23||$1.25||$1.23|
|04 May 2022||$1.23||$-0.01||-0.81%||826,738||$1.26||$1.26||$1.23|
|03 May 2022||$1.24||$0.00||0.00%||810,787||$1.24||$1.26||$1.24|
|02 May 2022||$1.24||$0.00||0.00%||325,884||$1.21||$1.24||$1.20|
|29 Apr 2022||$1.24||$0.00||0.00%||1,405,680||$1.22||$1.25||$1.22|
|28 Apr 2022||$1.24||$-0.01||-0.80%||1,256,281||$1.21||$1.25||$1.21|
|27 Apr 2022||$1.25||$0.04||3.31%||790,342||$1.21||$1.25||$1.20|
|26 Apr 2022||$1.21||$-0.03||-2.43%||363,739||$1.21||$1.22||$1.19|
|22 Apr 2022||$1.24||$0.01||0.82%||353,229||$1.22||$1.24||$1.21|
|21 Apr 2022||$1.23||$0.01||0.82%||161,637||$1.24||$1.25||$1.20|
|23 Nov 2021||Michael Knaap||Issued||466||$438,196|| |
Issue of securities. 1,262,205 - Performance Rights
As per announcement on 24/11/2021.
|Ms Zita Peach||Non-Executive Director||Oct 2016|| |
Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for major industry players such as CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita's most recent executive position is Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Fresenius Kabi, a leading provider of pharmaceutical products and medical devices to hospitals. Previously, Ms Peach was Vice President, Business Development, for CSL Limited, a position she held for ten years. Zita is Chair of Pacific Smiles Group Limited. She is also a member of the Hudson Institute of Medical Research Board.
|Mr Josef Jerzy Czyzewski||Non-Executive Director||Jun 2014|| |
Mr Czyzewski has over 30 years of experience in senior finance positions and significant experience in the health industry. Josef has held the positions of CFO at Healthscope Limited, and more recently CFO/General Manager Strategy and Development at Spotless Group Limited following its takeover by private equity interests in 2012. Prior to that time, Josef held various senior finance positions with BHP Billiton including VP Finance and Corporate Treasurer. He is Chair of Risk Management Committee.
|Mr Richard Hugh Davis||Non-Executive ChairmanNon-Executive Director||Jun 2014|| |
Mr Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is Member of Risk Management Committee.
|Mr Neil John Broekhuizen||Non-Executive Director||Jun 2014|| |
Mr Broekhuizen is the Joint Chief Executive Officer of Ironbridge. Neil has over 30 years experience in the finance industry, including 28 years in private equity with Investcorp and Bridgepoint in Europe, and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. Neil is currently the Independent Non-executive Chairman of Bravura Solutions, having previously served as a director. He is Member of Risk Management Committee.
|Mr Michael Damian Knaap||Chief Executive OfficerManaging Director||Sep 2015|| |
Mr Knaap has 20 years of experience in executive positions in operational, strategic and leadership background. Prior to joining MVF Group, Michael
was with Patties Foods Limited where he held a number of executive positions over six years, including the role of Chief Financial Officer and Company Secretary.
|Dr Richard Charles Henshaw||Executive Director||Apr 2014|| |
Dr Henshaw has practiced in the field of reproductive medicine since 1995. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
|Ms Catherine Jane West||Non-Executive Director||Sep 2020|| |
Ms West is an experienced ASX listed non-executive director and has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe. Her knowledge covers commercial arrangements, corporate transactions and joint ventures, intellectual property, regulatory policy, media and advertising, consumer issues, remuneration, risk management, corporate governance and compliance, together with providing consultancy to the healthcare sector and to media companies internationally. Catherine is a non-executive director of ASX listed Nine Entertainment where she is Chair of the People and Remuneration Committee and a member of the Audit and Risk Committee. She was previously on the board of Southern Phone, a regional telecommunications company, before its sale to AGL. She currently holds positions of Vice-President of the Sydney Breast Cancer Foundation at Chris O'Brien Lifehouse, director of the NIDA Foundation and a Governor of Wenona School.
|Mr Malik Jainudeen||Chief Financial OfficerCompany Secretary||Apr 2019|| |
|Malik Jainudeen||Chief Financial OfficerCompany Secretary|| |
|J P Morgan Nominees Australia Pty Limited||66,595,376||17.09%|
|Citicorp Nominees Pty Limited||65,624,403||16.84%|
|HSBC Custody Nominees (Australia) Limited||54,722,835||14.04%|
|National Nominees Limited||41,179,976||10.57%|
|Argo Investments Limited||19,982,646||5.13%|
|BNP Paribas Nominees Pty Ltd (Agency Lending Drp A/C)||18,851,171||4.84%|
|Cs Fourth Nominees Pty Limited (Hsbc Cust Nom Au Ltd 11 A/C)||6,784,523||1.74%|
|Brispot Nominees Pty Ltd (House Head Nominee A/C)||5,388,019||1.38%|
|HSBC Custody Nominees (Australia) Limited A/C 2||4,879,377||1.25%|
|BNP Paribas Noms Pty Ltd (Drp)||3,407,584||0.87%|
|Ubs Nominees Pty Ltd||3,199,536||0.82%|
|Neweconomy Com Au Nominees Pty Limited (900 Account)||2,483,708||0.64%|
|Pacific Custodians Pty Limited (Ordinary Unit Tst A/C)||2,474,369||0.63%|
|Ippoliti Pty Ltd (Ordinary Family Trust A/C)||2,011,336||0.52%|
|Vollenhoven Investments Pty Ltd (Vollenhoven Family A/C)||1,478,787||0.38%|
|Mr Prashant Nadkarni||1,461,484||0.38%|
|Dr Robert Ian Mclachlan & Mrs Edwina Margaret Mclachlan (R & E Mclachlan S/F A/C)||1,385,944||0.36%|
|BNP Paribas Nominees Pty Ltd (Ib Au Noms Retail Client Drp)||1,384,809||0.36%|
|Payne Media Pty Ltd||1,300,850||0.33%|
|BNP Paribas Nominees Pty Ltd (Ioof Insmt Mgmt Ltd Drp)||1,300,000||0.33%|